Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Laith JAbu-Raddad;
Hiam Chemaitelly ;
Houssein HAyoub;
Hadi MYassine;
Fatiha MBenslimane;
Hebah AAl Khatib;
PatrickTang;
Mohammad RHasan;
PeterCoyle;
SawsanAlMukdad;
+14 more...
ZainaAl Kanaani;
EinasAl Kuwari;
AndrewJeremijenko;
Anvar HassanKaleeckal;
Ali NizarLatif;
Riyazuddin MohammadShaik;
Hanan FAbdul Rahim;
Gheyath KNasrallah;
Mohamed GhaithAl Kuwari;
Adeel AButt;
Hamad EidAl Romaihi;
Mohamed HAl-Thani;
AbdullatifAl Khal;
RobertoBertollini;
(2021)
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1).
e1188-e1191.
ISSN 1058-4838
DOI: 10.1093/cid/ciab909
Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.
Item Type | Article |
---|---|
Elements ID | 166806 |
Downloads
Share this file
Explore Further
Read more research from the creator(s):
Find work associated with the faculties and division(s):
Find work associated with the research centre(s):
Find work from this publication:
ORCID: https://orcid.org/0000-0002-8756-6968